ElectroCore Appoints Kelly Benning as SVP of Truvaga to Drive Direct-to-Consumer Strategy and Expand Market Footprint

ElectroCore, a bioelectronic medicine and wellness company, has appointed Kelly Benning as SVP of Truvaga. Benning brings 30 years of experience in digital health, AI technologies, and consumer wellness. She will focus on expanding direct-to-consumer market access for electroCore's consumer wellness division, Truvaga. CEO Dan Goldberger expressed confidence in Benning's ability to expand electroCore's market footprint.

ElectroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has appointed Kelly Benning as the Senior Vice President of Truvaga, effective July 21, 2025. Ms. Benning brings nearly three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness. She will focus on expanding direct-to-consumer market access for electroCore's consumer wellness division, Truvaga.

Benning, who currently serves as Senior Vice President of Truvaga, is known for her expertise in bringing pioneering digital health products to market. She successfully led the development and commercialization of the first and only FDA-cleared watch to monitor blood pressure. Her interest in AI and machine learning has driven continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.

Throughout her career, Benning has collaborated with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. Prior to joining electroCore, she held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. She holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.

CEO Dan Goldberger expressed confidence in Benning's ability to expand electroCore's market footprint. "Bringing a proven and accomplished executive like Kelly to electroCore is the first of several benefits from our accelerating investment to support electroCore’s growth," he commented. "I am confident that Kelly has the right skills to expand our direct-to-consumer strategy."

ElectroCore's mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The company's leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its Truvaga™ products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.

References:
[1] https://www.marketscreener.com/news/electrocore-inc-announces-appointment-of-kelly-benning-as-senior-vice-president-of-truvaga-effect-ce7c51dadb8ff124
[2] https://www.globenewswire.com/news-release/2025/08/12/3131622/0/en/electroCore-Names-Kelly-Benning-Accomplished-Healthcare-Executive-as-SVP-of-Truvaga.html
[3] https://www.morningstar.com/news/globe-newswire/9510583/electrocore-names-kelly-benning-accomplished-healthcare-executive-as-svp-of-truvaga